Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) has received an average rating of “Buy” from the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports.

Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality- Global Phase 1 study of CLN-978 in systemic lupus ...

After hours: January 17 at 4:20:00 PM EST Loading Chart for CGEM ...

PRAX Praxis Precision Medicines, Inc.

Turmoil is brewing in the small town of Cullinan over an informal settlement coming their way. The City of Tshwane (CoT) announced plans late last year to buy an agricultural property in Cullinan ...

As they finally filed onto the court, with many of the players wearing puffy gray school coats, they were led out by seniors Nick Purdie, Patrick Cullinan and Jahyden Clark. Cullinan, Clark and ...

Leerink Partners decreased their target price on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 13th.